Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqGS - Nasdaq Real Time Price USD

Monte Rosa Therapeutics, Inc. (GLUE)

Compare
4.4300
-0.2100
(-4.53%)
At close: April 1 at 4:00:02 PM EDT
4.9900
+0.56
+(12.64%)
Pre-Market: 4:18:34 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
75,622
75,622
--
--
--
Operating Expense
156,734
156,734
143,311
112,384
72,882
Operating Income
-81,112
-81,112
-143,311
-112,384
-72,882
Net Non Operating Interest Income Expense
10,566
10,566
9,334
3,764
46
Other Income Expense
416
416
-1,037
119
-1,122
Pretax Income
-70,130
-70,130
-135,014
-108,501
-73,958
Tax Provision
2,570
2,570
338
--
--
Net Income Common Stockholders
-72,700
-72,700
-135,352
-108,501
-73,958
Diluted NI Available to Com Stockholders
-72,700
-72,700
-135,352
-108,501
-73,958
Basic EPS
-0.98
--
-2.63
-2.30
-2.96
Diluted EPS
-0.98
--
-2.63
-2.30
-2.96
Basic Average Shares
73,910.0260
--
51,396.9610
47,227.3700
25,000.1240
Diluted Average Shares
73,910.0260
--
51,396.9610
47,227.3700
25,000.1240
Total Operating Income as Reported
-81,112
-81,112
-143,311
-112,384
-72,882
Total Expenses
156,734
156,734
143,311
112,384
72,882
Net Income from Continuing & Discontinued Operation
-72,700
-72,700
-135,352
-108,501
-73,958
Normalized Income
-73,028.6400
-73,028.6400
-134,532.7700
-108,620
-73,796
Interest Income
10,566
10,566
9,334
3,764
46
Net Interest Income
10,566
10,566
9,334
3,764
46
EBIT
-81,112
-81,112
-143,311
-112,384
-72,882
EBITDA
-72,991
-72,991
-137,089
-108,639
-70,750
Reconciled Depreciation
8,121
8,121
6,222
3,745
2,132
Net Income from Continuing Operation Net Minority Interest
-72,700
-72,700
-135,352
-108,501
-73,958
Total Unusual Items Excluding Goodwill
416
416
-1,037
119
-162
Total Unusual Items
416
416
-1,037
119
-162
Normalized EBITDA
-73,407
-73,407
-136,052
-108,758
-70,588
Tax Rate for Calcs
0.0002
0.0002
0.0002
--
--
Tax Effect of Unusual Items
87.3600
87.3600
-217.7700
--
--
12/31/2021 - 6/24/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

TYRA Tyra Biosciences, Inc.
8.72
-6.24%
 
TCRX TScan Therapeutics, Inc.
1.2700
-7.97%
 
KYMR Kymera Therapeutics, Inc.
25.24
-7.80%
 
DNTH Dianthus Therapeutics, Inc.
16.83
-7.22%
 
RLYB Rallybio Corporation
0.6100
-6.80%
 
IPSC Century Therapeutics, Inc.
0.4518
-5.08%
 
CGEM Cullinan Therapeutics, Inc.
7.50
-0.92%
 
RVMD Revolution Medicines, Inc.
33.62
-4.92%
 
RLAY Relay Therapeutics, Inc.
2.4700
-5.73%
 
NRIX Nurix Therapeutics, Inc.
10.47
-11.87%